statementSaid on 2026-11-11
After acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
復星通過併購直接切入已上市產品,控股收購綠谷醫藥後,將用於輕至中度阿爾茨海默病的甘露特鈉膠囊納入創新藥管線,並承接其上市後確證性臨床研究。